These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 8758934

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Elevated levels of Mr 92,000 type IV collagenase during tumor growth in vivo.
    Sawaya R, Go Y, Kyritisis AP, Uhm J, Venkaiah B, Mohanam S, Gokaslan ZL, Rao JS.
    Biochem Biophys Res Commun; 1998 Oct 20; 251(2):632-6. PubMed ID: 9792825
    [Abstract] [Full Text] [Related]

  • 4. Regulatory mechanisms for the expression of type IV collagenases/gelatinases in murine macrophages.
    Xie B, Dong Z, Fidler IJ.
    J Immunol; 1994 Apr 01; 152(7):3637-44. PubMed ID: 8144939
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis.
    Sugiura Y, Shimada H, Seeger RC, Laug WE, DeClerck YA.
    Cancer Res; 1998 May 15; 58(10):2209-16. PubMed ID: 9605768
    [Abstract] [Full Text] [Related]

  • 8. Matrix metalloproteinase (MMP) inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer.
    Zervos EE, Shafii AE, Rosemurgy AS.
    J Surg Res; 1999 Jan 15; 81(1):65-8. PubMed ID: 9889060
    [Abstract] [Full Text] [Related]

  • 9. Increased type IV collagen-degrading activity in metastases originating from primary tumors of the human colon.
    Karakiulakis G, Papanikolaou C, Jankovic SM, Aletras A, Papakonstantinou E, Vretou E, Mirtsou-Fidani V.
    Invasion Metastasis; 1997 Jan 15; 17(3):158-68. PubMed ID: 9702942
    [Abstract] [Full Text] [Related]

  • 10. Membrane-type 1 matrix metalloproteinase-mediated progelatinase A activation in non-tumorigenic and tumorigenic human keratinocytes.
    Baumann P, Zigrino P, Mauch C, Breitkreutz D, Nischt R.
    Br J Cancer; 2000 Nov 15; 83(10):1387-93. PubMed ID: 11044366
    [Abstract] [Full Text] [Related]

  • 11. [Expression of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) in joint tissues of rapidly destructive coxarthropathy (RDC), analyzed by immunohistochemical study].
    Matsumoto F, Uzuki M, Kaneko C, Rikimaru A, Kokubun S, Sawai T.
    Ryumachi; 1997 Oct 15; 37(5):688-95. PubMed ID: 9396371
    [Abstract] [Full Text] [Related]

  • 12. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.
    Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Garbisa S, Mignatti P.
    EMBO J; 1997 May 01; 16(9):2319-32. PubMed ID: 9171346
    [Abstract] [Full Text] [Related]

  • 13. The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation.
    Paju A, Sorsa T, Tervahartiala T, Koivunen E, Haglund C, Leminen A, Wahlström T, Salo T, Stenman UH.
    Br J Cancer; 2001 May 18; 84(10):1363-71. PubMed ID: 11355948
    [Abstract] [Full Text] [Related]

  • 14. Measuring gelatinase activity in colorectal cancer.
    Baker EA, Leaper DJ.
    Eur J Surg Oncol; 2002 Feb 18; 28(1):24-9. PubMed ID: 11869009
    [Abstract] [Full Text] [Related]

  • 15. Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells.
    Janowska-Wieczorek A, Marquez LA, Matsuzaki A, Hashmi HR, Larratt LM, Boshkov LM, Turner AR, Zhang MC, Edwards DR, Kossakowska AE.
    Br J Haematol; 1999 May 18; 105(2):402-11. PubMed ID: 10233411
    [Abstract] [Full Text] [Related]

  • 16. A study of metalloproteinases in fifty joint fluid specimens.
    Gaudin P, Razakaboay M, Surla A, Berthier S, Fauconnier J, Morel F, Phelip X.
    Rev Rhum Engl Ed; 1997 Jun 18; 64(6):375-81. PubMed ID: 9513609
    [Abstract] [Full Text] [Related]

  • 17. Modulation of MMP-2 (gelatinase A) and MMP-9 (gelatinase B) by interferon-gamma in a human salivary gland cell line.
    Wu AJ, Lafrenie RM, Park C, Apinhasmit W, Chen ZJ, Birkedal-Hansen H, Yamada KM, Stetler-Stevenson WG, Baum BJ.
    J Cell Physiol; 1997 May 18; 171(2):117-24. PubMed ID: 9130458
    [Abstract] [Full Text] [Related]

  • 18. Neuropeptides induce Mr 92,000 type IV collagenase (matrix metalloprotease-9) activity in human prostate cancer cell lines.
    Sehgal I, Thompson TC.
    Cancer Res; 1998 Oct 01; 58(19):4288-91. PubMed ID: 9766654
    [Abstract] [Full Text] [Related]

  • 19. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients.
    Iizasa T, Fujisawa T, Suzuki M, Motohashi S, Yasufuku K, Yasukawa T, Baba M, Shiba M.
    Clin Cancer Res; 1999 Jan 01; 5(1):149-53. PubMed ID: 9918213
    [Abstract] [Full Text] [Related]

  • 20. Tumor cell invasion through matrigel is regulated by activated matrix metalloproteinase-2.
    Deryugina EI, Luo GX, Reisfeld RA, Bourdon MA, Strongin A.
    Anticancer Res; 1997 Jan 01; 17(5A):3201-10. PubMed ID: 9413149
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.